AI Article Synopsis
- Huntington's disease (HD) is a genetic neurodegenerative disorder caused by a mutation in the huntingtin gene, with currently only symptom management available.
- Recent studies suggest that metformin, a diabetes medication, may reduce the harmful effects of mutant huntingtin in animal models.
- This research analyzes data from the Enroll-HD database, finding that metformin use is linked to improved cognitive function in HD patients.
Article Abstract
Huntington's disease (HD) is an inherited, dominant neurodegenerative disorder caused by an abnormal expansion of CAG triplets in the huntingtin gene (htt). Despite extensive efforts to modify the progression of HD thus far only symptomatic treatment is available. Recent work suggests that treating invertebrate and mice HD models with metformin, a well-known AMPK activator which is used worldwide to treat type 2-diabetes, reduces mutant huntingtin from cells and alleviates many of the phenotypes associated to HD. Herein we report statistical analyses of a sample population of participants in the Enroll-HD database, a world-wide observational study on HD, to assess the effect of metformin intake in HD patients respect to cognitive status using linear models. This cross-sectional study shows for the first time that the use of metformin associates with better cognitive function in HD patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478119 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179283 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!